Prior authorization and step therapy for rheumatology biologics.
Every rheumatology biologic prior authorization turns on three facts a payer checks first: which benefit the drug bills under, how fast the plan is legally required to answer, and whether the chart proves the step therapy trail with dates instead of adjectives. This guide covers the Medicare Advantage step-therapy rule for Part B biologics, the decision deadlines that actually apply, DAS28/CDAI documentation that survives a coverage review, and the administration-route split that decides whether a drug goes through medical-benefit or pharmacy-benefit prior auth at all.
Key takeaways
- Part B versus Part D decides which rulebook applies. Infused biologics like infliximab and rituximab bill under the medical benefit, where the Medicare Advantage step-therapy rule and federal decision deadlines apply. Oral JAK inhibitors and most self-injected biologics bill under the pharmacy benefit, where they don't.
- MA plans can require step therapy on Part B biologics since January 1, 2019 — but only for new starts, never to switch a stable patient, and never as a means to deny a medically necessary service outright (HPMS memo, August 7, 2018).
- A standard Part B drug determination has a hard, non-extendable 72-hour clock under 42 CFR § 422.568 — a tighter deadline than the 7- or 14-day windows that apply to most other prior-auth-subject services.
- DAS28-ESR above 5.1 or CDAI above 10 is the objective bar most payers accept as proof disease remains active despite conventional therapy — a note that says "still symptomatic" without a scored value is a weaker submission than one with a dated score attached.
Which benefit it bills under decides the rule
The fact that determines which prior-authorization framework governs a rheumatology biologic isn't the diagnosis or the payer — it's the route of administration. A drug infused or injected in the office by clinical staff is physician-administered and bills under the Medicare Part B medical benefit (or its commercial equivalent). A drug the patient self-injects at home or swallows is typically dispensed through a pharmacy and bills under Part D or a commercial pharmacy benefit — a different prior-authorization system with its own clock and appeal path.
| Drug | Route | Benefit | Typical step position |
|---|---|---|---|
| Adalimumab, etanercept | SC self-inject | Part D / pharmacy | First-line TNF inhibitor |
| Infliximab (and biosimilars) | IV infusion | Part B / medical | First-line TNF inhibitor, physician-administered |
| Golimumab (SC) / golimumab IV | Both formulations exist | Part D (SC) or Part B (IV) | TNF inhibitor |
| Abatacept, tocilizumab | SC or IV, both formulations exist | Part D (SC) or Part B (IV) | Typically after a TNF-inhibitor trial |
| Rituximab (and biosimilars) | IV infusion only | Part B / medical | Typically after TNF-inhibitor failure in RA; other indications per LCD |
| Belimumab | SC or IV, both formulations exist | Part D (SC) or Part B (IV) | SLE, after standard immunosuppressive therapy |
| Tofacitinib, upadacitinib, baricitinib | Oral | Part D / pharmacy only | JAK inhibitor, typically after TNF-inhibitor failure; boxed-warning label affects plan step position |
The drugs with both an SC and an IV version — abatacept, tocilizumab, belimumab — trip up authorization staff most, because switching formulations to solve a site-of-care problem also switches which prior-authorization system the drug runs through. Confirm the NDC and route on the authorization on file before assuming it covers whichever formulation the clinic actually administers.
Medicare Advantage step therapy for Part B biologics: what the rule actually allows
Original, fee-for-service Medicare does not apply step therapy to Part B drugs. Medicare Advantage is different: CMS rescinded its 2012 prohibition and, in an HPMS memo dated August 7, 2018, authorized MA plans to apply step therapy to Part B drugs as part of a patient-centered care coordination program, effective for plan years beginning January 1, 2019. The guidance carries real limits:
- 1New starts only. Step therapy applies only to a new prescription or administration of a Part B drug — an enrollee not already actively receiving that medication. A plan cannot force an established, stable patient off a biologic that's already working.
- 2Not a coverage denial tool. Step therapy may not be used to deny coverage of a medically necessary service or eliminate access to a Part B covered benefit — it can require trying a covered alternative first, but it cannot end coverage entirely.
The appeal argument when a step-therapy denial hits an already-stable patient isn't a coverage argument — it's a policy-scope one. Cite the August 2018 HPMS memo by name, state that the patient was actively receiving the medication before the request was submitted, and ask the plan to confirm its program applies only to new starts as CMS requires. That resolves faster than a medical-necessity appeal, because it asks the plan to apply its own policy correctly, not to re-judge the clinical picture.
How fast the payer has to decide
Medicare Advantage organization-determination timelines are federal, not plan-specific, and the clock for Part B drugs is shorter than for almost anything else a plan reviews.
| Request type | Deadline |
|---|---|
| Standard determination, item not on the plan's prior-authorization list | 14 calendar days |
| Standard determination, item subject to prior authorization (effective January 1, 2026) | 7 calendar days |
| Part B drug determination, standard | 72 hours — cannot be extended |
| Expedited determination (any service or item) | 72 hours |
The 72-hour Part B drug deadline is worth a tracking workflow of its own, because it isn't subject to the extension provisions that apply to other standard determinations — a plan can't push it out for missing records or "extraordinary circumstances." A Part B biologic authorization pending past 72 hours with no determination is a clock violation worth escalating directly, not a status update to wait on.
⚠️ The 7-calendar-day timeline for prior-auth-subject items, effective January 1, 2026, comes from CMS's Interoperability and Prior Authorization Final Rule (CMS-0057-F); this build could not open the CMS.gov fact sheet directly to re-confirm which plan types it binds (cms.gov returned an access error to automated fetch attempts), so treat that scope as reported consistently across secondary sources rather than independently re-verified, and confirm against the specific plan's own policy before relying on it in an appeal.
Documenting step therapy so it survives review
A payer's utilization reviewer is trained to look for two things on a biologic prior-auth submission: a named conventional therapy trial with dates, and an objective disease-activity score, not a narrative description of how the patient is doing.
| Score | What it measures | Threshold generally read as "active" |
|---|---|---|
| DAS28-ESR / DAS28-CRP | 28 tender/swollen joint counts, patient global health, and ESR or CRP | >5.1 high activity · 3.2–5.1 moderate · <3.2 low · <2.6 remission |
| CDAI | 28 tender/swollen joint counts plus patient and physician global assessment — no lab value | >22 high · 10–22 moderate · ≤10 low disease activity · ≤2.8 remission |
CDAI is worth defaulting to for prior-auth submissions because it doesn't need a same-day lab draw — scored entirely from the exam and two global assessments, so a value is available at every visit. A DAS28 or CDAI score above the moderate-to-high threshold, dated to the visit where the step-up decision was made, is the strongest single piece of evidence in a biologic authorization packet.
- 1Name each DMARD trial individually — drug, dose, duration, and why it stopped (inadequate response, intolerance, or contraindication). "Failed conventional therapy" without specifics is the most common reason a submission gets sent back for more information.
- 2Attach the scored value, not just the interpretation. "DAS28-ESR 5.4 on 06/12/2026" survives a reviewer's second look; "disease remains active" does not.
- 3List prior biologic failures by drug name and date, not as a category. A policy requiring one TNF-inhibitor failure before a non-TNF biologic is checking for a specific drug and date, not the concept of "tried a biologic before."
Site-of-care denials are a different fight
A payer requiring an infused biologic to move from the physician's office to a lower-cost infusion center isn't questioning whether the drug is necessary — it's questioning where it's given, and the appeal has to match that. Restating the clinical case for the drug doesn't address it; the payer isn't disputing that. What overturns a site-of-care denial is a specific, documented reason the office setting is required: a prior infusion-reaction history, a comorbidity needing on-site monitoring an infusion center doesn't have, or a documented access barrier. Submit it as its own request with its own justification, not folded into the original biologic authorization.
Build the peer-to-peer call around the same specifics as the original submission, not a restatement of the diagnosis. A reviewer who hears "the patient has rheumatoid arthritis and needs a biologic" a second time has nothing new to approve against. Walking through the exact DMARD trial dates, why each one stopped, and the disease-activity trajectory over time is the highest-yield five minutes in the entire denial workflow.
Reauthorization cadence by drug class
- TNF inhibitors and established-response non-TNF biologics typically renew on a 12-month cycle with a continuation-of-therapy attestation, once the initial step-therapy trail is on file — an unchanged dose and a low/remission disease-activity score are usually enough.
- JAK inhibitors often carry a shorter interval — commonly 6 months — tied to boxed-warning monitoring for infection, malignancy, and cardiovascular risk. A dose escalation or in-class switch resets the clock and needs fresh disease-activity documentation, not a carryover of the original justification.
Losing time to rheumatology biologic prior auths?
We'll review your current prior-authorization workflow, flag where the Part B 72-hour clock is being missed, and show what a tighter DAS28/CDAI documentation process would recover.
Frequently asked questions
How fast does a Medicare Advantage plan have to decide a Part B biologic prior authorization?
For a Part B drug request specifically, 42 CFR 422.568 sets a 72-hour deadline that cannot be extended under any of the usual extension provisions — not for missing records, not for extraordinary circumstances. That's tighter than the general standard organization-determination clock, which is 14 calendar days for a service not subject to the plan's prior-authorization list, or 7 calendar days for one that is, effective January 1, 2026. Expedited requests for other services and items carry their own 72-hour deadline, but the Part B drug rule applies on its own terms regardless of whether the request was filed as expedited.
Can a Medicare Advantage plan apply step therapy to a patient who's already stable on a biologic?
No. CMS's August 2018 guidance, effective January 1, 2019, permits Medicare Advantage plans to apply step therapy to Part B drugs only for new prescriptions or new administrations — an enrollee not already receiving the affected medication. A patient stable on an infused biologic can't be switched or forced to fail a different drug first as a condition of continued coverage under this policy, and step therapy can't be used to deny a medically necessary service or eliminate access to a covered Part B benefit outright.
Does step therapy work the same way for an oral JAK inhibitor as it does for an infused biologic?
No, because they're rarely billed under the same benefit. Infused biologics like infliximab and rituximab are physician-administered and billed under the Medicare Part B medical benefit, which is where the Medicare Advantage step-therapy rule and the 42 CFR 422.568 timelines apply. Oral JAK inhibitors are typically dispensed through a pharmacy and billed under Part D or a commercial pharmacy benefit, where step therapy runs through the plan's formulary and utilization-management rules instead — a different review process with its own appeal path, not the Part B organization-determination framework.
Verify before billing. CPT is a registered trademark of the American Medical Association; codes here are paraphrased, not reproduced from the CPT Professional edition. CPT, HCPCS and ICD-10 codes, coverage policy, and bundling edits change, including annual code-set updates. This page reflects standard industry practice and is provided for general education — it is not a substitute for your own compliance review, your current payer contracts, or the current-year code sets. Confirm requirements against your specific payer mix before submitting claims.